Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Buda

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
European Journal of Preventive Cardiology|March 8, 2024
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening studyAlberto Aimo, Giuseppe Vergaro, Vincenzo Castiglione, et al.
Leukemia & Lymphoma|June 14, 2011
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantStefano Sacchi, Raffaella Marcheselli, Antonio Lazzaro, et al.
Journal of Human Genetics|January 11, 2013
Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortiumAlessandro Martino, Juan Sainz, Rui Manuel Reis, et al.
Haematologica|February 10, 2016
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana LinfomiStefano Sacchi, Raffaella Marcheselli, Alessia Bari, et al.
Frontiers in Oncology|July 12, 2019
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid LeukemiaSusanna Grassi, Sara Palumbo, Veronica Mariotti, et al.
International Journal of Oncology|December 14, 2011
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review)Alessandro Martino, Juan Sainz, Gabriele Buda, et al.
Cancer Cell International|April 18, 2019
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patientsSerena Salehzadeh, Francesca Guerrini, Umberto Pizzano, et al.
Hematological Oncology|October 21, 2020
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myelomaSerena Rocchi, Paola Tacchetti, Lucia Pantani, et al.
Hematological Oncology|October 3, 2012
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian InstitutionsSimona Falorio, Irene Biasoli, Stefano Luminari, et al.
European Journal of Heart Failure|January 4, 2023
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosisGiuseppe Vergaro, Vincenzo Castiglione, Alberto Aimo, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
European Journal of Preventive Cardiology|March 8, 2024
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening studyAlberto Aimo, Giuseppe Vergaro, Vincenzo Castiglione, et al.
Leukemia & Lymphoma|June 14, 2011
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantStefano Sacchi, Raffaella Marcheselli, Antonio Lazzaro, et al.
Journal of Human Genetics|January 11, 2013
Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortiumAlessandro Martino, Juan Sainz, Rui Manuel Reis, et al.
Haematologica|February 10, 2016
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana LinfomiStefano Sacchi, Raffaella Marcheselli, Alessia Bari, et al.
Frontiers in Oncology|July 12, 2019
The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid LeukemiaSusanna Grassi, Sara Palumbo, Veronica Mariotti, et al.
International Journal of Oncology|December 14, 2011
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review)Alessandro Martino, Juan Sainz, Gabriele Buda, et al.
Cancer Cell International|April 18, 2019
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patientsSerena Salehzadeh, Francesca Guerrini, Umberto Pizzano, et al.
Hematological Oncology|October 21, 2020
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myelomaSerena Rocchi, Paola Tacchetti, Lucia Pantani, et al.
Hematological Oncology|October 3, 2012
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian InstitutionsSimona Falorio, Irene Biasoli, Stefano Luminari, et al.
European Journal of Heart Failure|January 4, 2023
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosisGiuseppe Vergaro, Vincenzo Castiglione, Alberto Aimo, et al.
Pageof 14